Jaguar Health, Inc. is a commercial-stage pharmaceuticals company focused on developing and commercializing plant-based gastrointestinal products for humans and animals. Its current business is organized around two segments, Human Health and Animal Health, covering prescription and non-prescription products for conditions such as chronic diarrhea, bowel urgency, and related gastrointestinal distress. The company’s human portfolio includes therapies for HIV-related diarrhea and other gastrointestinal indications, while its animal health activities target companion and production animals with digestive health needs. Jaguar Health also works through its subsidiaries to support proprietary products derived from sustainably sourced botanical ingredients. Headquartered in San Francisco, California, Jaguar Health plays a specialized role in the pharmaceutical market by addressing gastrointestinal disorders across both human and veterinary care.
Website200 Pine Street
San Francisco, CA, 94104
United States
Jaguar Health is surging on a float so thin that a handful of trades can swing the price wildly, while a rare pediatric disease program edges closer to a pivotal regulatory filing that could either validate the rally or expose how fragile it really is.
Jaguar Health is surging Friday after announcing debt-for-equity exchanges that cut debt by over $6.7 million and retired a promissory note.
Jaguar Health shares are sliding Thursday as equity dilution concerns weigh on the company following a debt-for-equity exchange.
Two biotech stocks are getting crushed while the sector benchmark climbs, and the reasons behind each selloff could not be more different. Understanding what separates a deliberate corporate move from pure micro-cap chaos is the key to reading both situations correctly.
Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 216.1% to $13.12 during Wednesday's regular session. The market value of their outstanding shares is at $2.2 million. Vistagen Therapeutics (NASDAQ:VTGN) shares
Investors talking about JAGX also mention
| # | Name | Attention |
|---|---|---|
| 1 | AVGR - Avinger, Inc. | —— |
| 2 | NVCN - Neovasc Inc. | —— |
| 3 | InspireMD, Inc.NSPR | 0%new |
| 4 | Bionano Genomics Inc.BNGO | 0%0 |
| 5 | Check-Cap Ltd.CHEK | 0%new |
| 6 | Top Ships Inc.TOPS | 0%+0 |
| 7 | My Size, Inc.MYSZ | 0%new |
| 8 | OBLN - Obalon Therapeutics, Inc. | —— |
| 9 | Lm Funding America Inc.LMFA | 0%new |
| 10 | Oragenics Inc.OGEN | 0%0 |
What share of all stock conversation is about JAGX?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0.02% -0.02 | 0.08% +0.04 | 0.02% +0.02 | 0% 0 |
Of the messages about JAGX that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 81.94% +17.77 | 72.05% -0.12 | 71.71% -11.15 | 65.56% +4.82 | ||
| Bearish | 18.06% -17.77 | 27.95% +0.12 | 28.29% +11.15 | 34.44% -4.82 |
Of the messages about JAGX that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | 100% | 5.15% | 8.12% | 20.93% | ||
| Technical Analysis | 0% | 16% | 18.02% | 15.02% | ||
| Analysts | 0% | 39.69% | 37.23% | 30.63% | ||
| Earnings | 0% | 0% | 0% | 1.63% | ||
| Macro | 0% | 39.06% | 36.55% | 31.72% | ||
| Controversies | 0% | 0.09% | 0.08% | 0.07% |
Of the messages about JAGX, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 32.89% | 23.99% | 24.5% | 33.37% | ||
| Newcomers | 67.11% | 76.01% | 75.5% | 66.63% |